We are live on ! Find out more
KIN

Kindred Biosciences, Inc.
KIN

Delisted

KIN was delisted on the 27th of August, 2021.

81 hedge funds and large institutions have $314M invested in Kindred Biosciences, Inc. in 2018 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 36 increasing their positions, 17 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

112% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 17

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

67% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 12

63% more call options, than puts

Call options by funds: $252K | Put options by funds: $155K

39% more capital invested

Capital invested by funds: $226M → $314M (+$88M)

11% more funds holding

Funds holding: 7381 (+8)

Holders
81
Holders Change
+8
Holders Change %
+10.96%
% of All Funds
1.85%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.05%
New
20
Increased
36
Reduced
17
Closed
12
Calls
$252K
Puts
$155K
Net Calls
+$97K
Net Calls Change
+$449K
Name Holding Trade Value Shares
Change
Change in
Stake
EAM
51
Evanson Asset Management
California
$231K
II
52
Ibex Investors
Colorado
$217K +$210K +15,555 New
Susquehanna International Group
53
Susquehanna International Group
Pennsylvania
$204K -$246K -18,172 -55%
JP Morgan Chase
54
JP Morgan Chase
New York
$201K -$95.9K -7,088 -33%
MIM
55
MetLife Investment Management
New Jersey
$191K
MF
56
Magnetar Financial
Illinois
$184K +$179K +13,209 New
Barclays
57
Barclays
United Kingdom
$173K +$122K +8,982 +264%
Manulife (Manufacturers Life Insurance)
58
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$171K -$143K -10,557 -46%
Millennium Management
59
Millennium Management
New York
$163K +$158K +11,653 New
VOYA Investment Management
60
VOYA Investment Management
Georgia
$159K
AAMU
61
Amundi Asset Management US
Massachusetts
$156K +$152K +11,200 New
AQR Capital Management
62
AQR Capital Management
Connecticut
$143K
MLICM
63
Metropolitan Life Insurance Company (MetLife)
New York
$135K
KF
64
Krilogy Financial
Missouri
$127K +$123K +9,090 New
MAM
65
Meeder Asset Management
Ohio
$122K +$55.8K +4,122 +90%
Citigroup
66
Citigroup
New York
$119K +$108K +7,998 +1,484%
Royal Bank of Canada
67
Royal Bank of Canada
Ontario, Canada
$84K -$27.7K -2,046 -25%
Legal & General Group
68
Legal & General Group
United Kingdom
$65K +$12.4K +920 +25%
HH
69
HWG Holdings
Texas
$46K +$44.6K +3,295 New
Federated Hermes
70
Federated Hermes
Pennsylvania
$36K +$3.88K +287 +12%
AIP
71
Ameritas Investment Partners
Nebraska
$26K
ML
72
McAdam LLC
Pennsylvania
$26K +$27.1K +2,000 New
FCMT
73
Founders Capital Management (Texas)
Texas
$21K -$6.76K -500 -25%
BNP Paribas Financial Markets
74
BNP Paribas Financial Markets
France
$18.5K +$5.2K +384 +41%
DWA
75
Dorsey Wright & Associates
California
$16K +$15.3K +1,129 New

KIN Hedge Fund Activity: Q3 2018 in Review

81 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Kindred Biosciences, Inc. (KIN) for Q3 2018, worth a combined $314M — up 39% from $226M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new KIN positions and 12 closed out — a net gain of 8 holders — while 36 added to existing stakes and 17 trimmed.

The largest buyer was BlackRock, adding an estimated $6.82M. The largest seller was Pacific View Asset Management, cutting an estimated $2.73M.

  • 81 institutional investors held Kindred Biosciences, Inc. (KIN) as of Q3 2018, up from 73 in Q2 2018.
  • Funds reported $314M of Kindred Biosciences, Inc. stock for Q3 2018, up 39% quarter-over-quarter.
  • 20 funds opened new Kindred Biosciences, Inc. positions in Q3 2018 and 12 closed out, a net change of +8 holders.
  • The largest Kindred Biosciences, Inc. buyer in Q3 2018 was BlackRock, an estimated $6.82M added.
  • The largest Kindred Biosciences, Inc. seller in Q3 2018 was Pacific View Asset Management, an estimated $2.73M sold.

Based on aggregated 13F filings for Q3 2018.